Global Digital Therapeutics Market valued at $2.2bn, poised to transform the Digital Health Segment

The global digital therapeutics market pegged at $2.2 billion (2020) is set to gain momentum. The next phase of growth likely to be driven by growing pharma-digital therapeutic alliances, growing focus on mental health and psychiatric conditions.
 
BRUSSELS - Sept. 16, 2021 - PRLog -- Changing medical protocols, need to curtail costs, evolution and widespread adoption of technology specifically in the areas of artificial intelligence, deep learning and health monitoring using wearables is increasingly transforming healthcare and has paved the way for a new class of therapeutics known as digital therapeutics (DTx).

Digital therapeutics is poised to revolutionize the healthcare industry. It finds usage across a range applications such as Diabetes, Chronic Respiratory Disorders, Musculoskeletal Disorders, Smoking Cessation, Cardiovascular Diseases, CNS Disorders, Obesity and Others. It offers immense value for multiple stakeholders. Key stakeholders such as FDA, HCPs, Payers, and Patients are now increasing embracing digital therapeutics as a form of therapy.

Geographic Snapshot: Digital Therapeutics Market

Comprehensive regional assessment of the global digital therapeutics market covering U.S., Europe (Germany, Italy, France, Spain, UK, and Rest of Europe), Asia-Pacific (India, China, Japan, Australia, New Zealand, Singapore and Rest of Asia-Pacific) and Rest of the World (Latin America, Middle-East & Africa) suggests that U.S. is likely to continue its dominance in the next 10 years. Rising prevalence of chronic diseases, favorable government policies & grants, growing awareness regarding digital therapeutics & its benefits and well-developed healthcare infrastructure is set to catapult the U.S. digital therapeutics market. Facilitation of digital therapeutics led by Pharmacy Benefit Managers (PBMs) in the U.S. is also expected to fuel its adoption. For instance, in Dec 2019, Express Scripts announced that digital therapeutics solutions would be added to its digital health "formulary". In another instance, in June 2019, CVS Caremark unveiled a platform that enables payers to formalize and streamline the process for digital therapeutics reimbursement and distribution.

Psychiatry Remains #1 Application in Clinical Trials of Digital Therapeutics

A review of trends of digital therapeutics clinical trials over the past ten years suggests that with respect to therapeutic areas (TA) under investigation, the highest percentage of trials were conducted for psychiatry indication followed by cardiovascular, addiction, endocrinology, neurology, and respiratory indications. Strong pipeline of digital therapeutics products across diverse application areas – neuroscience indications, cardiovascular diseases, gastrointestinal diseases, chronic kidney disease (CKD), among others is likely to provide impetus to the global digital therapeutics market.

For Detailed Insights, Reach out to us @ https://meditechinsights.com/contact-us/

Contact
Avez Shaikh
aves.s@meditechinsights.com
+ 32 498868079
End
Email:***@meditechinsights.com Email Verified
Tags:Digital Therapeutics Market
Industry:Reports
Location:Brussels - Brussels - Belgium
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Medi-Tech Insights News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share